<DOC>
	<DOCNO>NCT00004194</DOCNO>
	<brief_summary>RATIONALE : Fludarabine may effective treatment graft-versus-host disease cause bone marrow transplantation . PURPOSE : Phase I/II trial study effectiveness fludarabine treat patient chronic graft-versus-host disease respond steroid therapy .</brief_summary>
	<brief_title>Fludarabine Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose , toxicity , efficacy fludarabine patient steroid resistant chronic graft versus host disease . OUTLINE : This dose escalation study . Phase I : Patients receive fludarabine IV le 30 minute 1-3 day . Treatment repeat every 4 week 4 course absence relapse underlie disease , malignancy , graft rejection , unacceptable toxicity . Patients progressive graft versus host disease completion 3 course take study . Patients complete response take study . Patients partial response may continue treatment immediate prior dose level . Cohorts 3-6 patient receive escalate dos fludarabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 6 patient experience dose limit toxicity . Phase II : Patients receive fludarabine MTD phase I study . PROJECTED ACCRUAL : A total 15-27 patient accrue study .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically clinically proven chronic graft versus host disease ( GVHD ) fail respond least 1 month treatment follow : Steroids ( great 0.5 mg/kg/day ) AND Cyclosporine cytotoxic agent ( azathioprine mercaptopurine ) OR Other experimental treatment ( chloroquine ) All allogeneic bone marrow peripheral blood stem cell transplantation patient eligible regardless underlie disease transplantation perform : At least 45 day since prior transplantation No relapse underlie disease No loss donor hematopoiesis Patients rapid deterioration GVHD consider life threaten control eligible receiving high dose steroid ( great 1 mg/kg/day ) least 10 day PATIENT CHARACTERISTICS : Age : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,300/mm3 Platelet count least 75,000/mm3 Hepatic : Not specify Renal : Creatinine great 2 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : No concurrent cytotoxic drug Endocrine therapy : Concurrent steroid allow must taper less 0.5 mg/kg/day prednisone equivalent prior start study drug ( symptomatic flare develop taper , patient may continue low dose think produce stabilization ) Radiotherapy : Not specify Surgery : Not specify Other : Concurrent cyclosporine nonmyelosuppressive drug allow No concurrent myelosuppressive agent ( azathioprine , mercaptopurine )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>graft versus host disease</keyword>
</DOC>